Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare reimbursement for personal exoskeletons established in 2024 Decision to cover device arrives shortly after the launch of the ReWalk 7 Personal Exoskeleton, which was released for sales in the U.S. earlier this month MARLBOROUGH, Mass. and YOKNEAM ILLIT, Is...
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- Seventh generation of industry-leading personal exoskeleton is now available nationwide for individuals with spinal cord injury
Seventh Generation of Industry-Leading Exoskeleton Includes New and Enhanced Features for Individuals with Spinal Cord Injury Seventh Generation of Industry-Leading Exoskeleton Includes New and Enhanced Features for Individuals with Spinal Cord Injury
Lifeward Ltd. (NASDAQ:LFWD ) Q4 2024 Earnings Conference Call March 7, 2025 8:30 AM ET Company Participants Mike Lawless - CFO Larry Jasinski - CEO Almog Adar - VP, Finance Conference Call Participants Yale Jen - Laidlaw & Company Ben Haynor - Lake Street Capital Markets Swayampakula Ramakanth - H.C.
Record quarterly and annual revenue of $7.5M and $25.7M, respectively Continued strong growth in U.S. pipeline of ReWalk opportunities with over 110 qualified leads in process Strategic s hift t owards p rofitability: 2025 Sustainable Growth Plan f ocuses on growth of c ore p roduct l ines with a s treamlined c ost s tructure and r educed o perating loss MARLBOROUGH, Mass. and YOKNEAM ILLIT, Is...
New Agreement Expands Distribution Rights to Lifeward to Include Referral Sales for Home Use Applications New Agreement Expands Distribution Rights to Lifeward to Include Referral Sales for Home Use Applications
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.